ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

NDRA ENDRA Life Sciences Inc

0.2525
0.01 (4.12%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ENDRA Life Sciences Inc NDRA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.01 4.12% 0.2525 16:15:13
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
0.252 0.2422 0.257299 0.2525 0.2425
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
28/3/202415:05BWENDRA Life Sciences Reports Fourth Quarter and Full Year..
21/3/202407:00BWENDRA Life Sciences to Report Fourth Quarter 2023 Financial..
27/2/202407:00BWENDRA Life Sciences Installs First TAEUS System in the UK
23/2/202416:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/2/202407:00BWNew ICD-10-CM Code by the World Health Organization Paves..
14/2/202407:30BWENDRA Life Sciences Bolsters TAEUS® System Intellectual..
29/12/202316:07EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
29/11/202307:00BWENDRA Life Sciences Secures 39th U.S. Patent for TAEUS®..
27/11/202307:00BWENDRA Life Sciences to Participate in The Benchmark..
14/11/202315:05BWENDRA Life Sciences Reports Third Quarter 2023 Financial..
14/11/202315:02EDGAR2Form 8-K - Current report
08/11/202307:00BWENDRA Life Sciences Achieves Intellectual Property Milestone..
07/11/202315:05BWENDRA Life Sciences to Report Third Quarter 2023 Financial..
06/11/202307:00BWENDRA to Host Multidisciplinary Clinical Discussion on..
07/9/202307:00BWAbstract for ENDRA Life Sciences' TAEUS System Accepted for..
30/8/202307:00BWENDRA Life Sciences' TAEUS De Novo Submission Advances to..
23/8/202307:00BWENDRA Life Sciences Expands Intellectual Property with..
14/8/202315:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202315:13EDGAR2Form 8-K - Current report
14/8/202315:05BWENDRA Life Sciences Reports Second Quarter 2023 Financial..
14/8/202312:30BWENDRA Life Sciences Submits De Novo Request for its TAEUS®..
10/8/202307:01EDGAR2Form 8-K - Current report
01/8/202307:00BWENDRA Life Sciences to Report Second Quarter 2023 Financial..
25/7/202315:02EDGAR2Form 8-K - Current report
06/7/202316:25EDGAR2Form 8-K - Current report
06/7/202316:25EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/7/202315:45BWENDRA Life Sciences Announces Adjournment of 2023 Annual..
07/6/202307:00BWStudy Highlighting ENDRA Life Sciences’ TAEUS Technology to..
15/5/202315:05BWENDRA Life Sciences Reports First Quarter 2023 Financial..
04/5/202307:00BWENDRA Life Sciences to Report First Quarter 2023 Financial..
02/5/202315:01BWENDRA Life Sciences Announces Closing of Public Offering and..
28/4/202307:00BWENDRA Life Sciences Announces Pricing of Upsized $4.5..

Su Consulta Reciente

Delayed Upgrade Clock